Dopamine Agonist

Fixed-Dose Tavapadon for Early Parkinson Disease: A Randomized Clinical Trial

In a phase 3 trial, once-daily tavapadon improved motor symptoms in people with early Parkinson disease and was generally well tolerated, with nausea, headache, and dizziness as the most common side effects.

Selective D1/D5 Receptor Agonism in Parkinson Disease: Insights from the TEMPO-3 Phase 3 Trial of Tavapadon